ArticleFrontiers in nutrition2026
Red cell distribution width to albumin ratio predicts short-term mortality in urosepsis: a dual-cohort study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of blood urea nitrogen to albumin ratio with short-term mortality in critically ill patients with urosepsis.Frontiers in medicine · 2026Article
- Association between lactate dehydrogenase-to-albumin ratio and short-term mortality in critically ill patients with urosepsis: evidence from dual retrospective cohorts.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methods: This study retrospectively collected data on patients with urosepsis from the MIMIC-IV database and Bijie Hospital of Zhejiang Provincial People's Hospital. Multiple statistical methods were employed to explore the association between the RAR and short-term adverse outcomes, including multivariable Cox regression, restricted cubic spline (RCS) regression, and Kaplan-Meier (KM) survival analyses. Subsequently, three machine learning algorithms were utilized to screen for important features, followed by the construction of a multivariable Cox regression model for risk prediction. The performance of the risk prediction model was evaluated using receiver operating characteristic (ROC) curve analysis, with comparative validation performed via DeLong's test. Results: This study ultimately included 3,374 patients with urosepsis. The 28-day ICU mortality and in-hospital mortality rates were 15.20 and 13.75%, respectively. In the fully adjusted multivariate models, RAR, whether treated as a continuous or categorical variable, remained significantly associated with both 28-day ICU mortality and in-hospital mortality. For each unit increase in continuous RAR, the hazard ratios (HRs) were 1.10 (95% confidence interval [CI]: 1.05-1.16) and 1.09 (95% CI: 1.04-1.15), respectively. Compared with the low-RAR group, the high-RAR group showed HRs of 1.55 (95% CI: 1.19-2.01) and 1.39 (95% CI: 1.06-1.82) for the two outcomes. RCS analysis indicated a positive dose-response relationship between RAR and short-term adverse prognosis. DeLong's test and ROC curve analysis demonstrated that RAR can appropriately enhance the predictive ability of routine critical illness scores for adverse outcomes. Moreover, a risk-prediction model incorporating RAR Slightly better than traditional severity scores (such as SOFA and SAPS II) in identifying high-risk patients. All findings were validated in an external cohort. Conclusion: This study suggests that the RAR could serve as a predictor of short-term mortality risk in patients with urosepsis, with potential for translation into a clinical stratification tool to aid early identification of high-risk patients and guide intervention. However, its clinical utility needs to be further validated in larger prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.